Eli Lilly's arthritis drug fails to meet main goal of late-stage Covid-19 study
Baricitinib has been granted emergency use authorization by the U.S. Food and Drug Administration in combination with remdesivir for Covid-19 patients requiring supplemental oxygen
FILE PHOTO: The logo and ticker for Eli Lilly and Co. are displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, US, May 18, 2018. REUTERS/Brendan McDermid
Rheumatoid arthritis drug baricitinib developed by Eli Lilly and Co and Incyte Corp did not meet the main goal of a late-stage study in hospitalized Covid-19 patients, the drugmakers said on Thursday.
Baricitinib has been granted emergency use authorization by the U.S. Food and Drug Administration in combination with remdesivir for Covid-19 patients requiring supplemental oxygen.
Keep updated, follow The Business Standard's Google news channel
